Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Morris D. Groves"'
Autor:
Priya U Kumthekar, Michael J Avram, Andrew B Lassman, Nancy U Lin, Eudocia Lee, Sean A Grimm, Margaret Schwartz, Kirsten L Bell Burdett, Rimas V Lukas, Karan Dixit, Isabella Perron, Hui Zhang, William J Gradishar, Elena I Pentsova, Suriya Jeyapalan, Morris D Groves, Michelle Melisko, Jeffrey J Raizer
Publikováno v:
Neuro-Oncology. 25:557-565
Background Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS pen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f77768f1b6a19e682c66e9d528a059e2
https://doi.org/10.1093/neuonc/noac195
https://doi.org/10.1093/neuonc/noac195
Autor:
Farshad Nassiri, Vikas Patil, Leeor S. Yefet, Olivia Singh, Jeff Liu, Rachel M. A. Dang, Takafumi N. Yamaguchi, Mariza Daras, Timothy F. Cloughesy, Howard Colman, Priya U. Kumthekar, Clark C. Chen, Robert Aiken, Morris D. Groves, Shirley S. Ong, Rohan Ramakrishna, Michael A. Vogelbaum, Simon Khagi, Thomas Kaley, Jason M. Melear, David M. Peereboom, Analiz Rodriguez, Maxim Yankelevich, Suresh G. Nair, Vinay K. Puduvalli, Kenneth Aldape, Andrew Gao, Álvaro López-Janeiro, Carlos E. de Andrea, Marta M. Alonso, Paul Boutros, Joan Robbins, Warren P. Mason, Adam M. Sonabend, Roger Stupp, Juan Fueyo, Candelaria Gomez-Manzano, Frederick F. Lang, Gelareh Zadeh
Publikováno v:
Nature Medicine.
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74942e6023caf7605d2728c0f0f56767
https://doi.org/10.1038/s41591-023-02347-y
https://doi.org/10.1038/s41591-023-02347-y
Autor:
Johann de Bono, Mohammed M. Dar, C. Martin Curtis, Bo Ma, A. Benjamin Suttle, Roger E. McLendon, Jorge Barriuso, Jeffrey Raizer, Steve Rosenfeld, Tom Mikkelsen, Louis Nabors, Patrick Y. Wen, Morris D. Groves, David A. Reardon
PDF file - 82K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb8954667ce67d039a6bd7b135b18a9
https://doi.org/10.1158/1078-0432.22450127.v1
https://doi.org/10.1158/1078-0432.22450127.v1
Autor:
Johann de Bono, Mohammed M. Dar, C. Martin Curtis, Bo Ma, A. Benjamin Suttle, Roger E. McLendon, Jorge Barriuso, Jeffrey Raizer, Steve Rosenfeld, Tom Mikkelsen, Louis Nabors, Patrick Y. Wen, Morris D. Groves, David A. Reardon
PDF file - 182K, Tumor reduction in 3 patients who achieved a partial response following (A) 21 days, (B) 15 months, and (C) 18 months of treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::555c9b5970fe8207a3720f2fdd5bb3a7
https://doi.org/10.1158/1078-0432.22450130.v1
https://doi.org/10.1158/1078-0432.22450130.v1
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e62bc045083f295b5505a4d2ceb22bf
https://doi.org/10.1158/1078-0432.22483670.v1
https://doi.org/10.1158/1078-0432.22483670.v1
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Purpose:FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4433b4500bfad782b57ee3a0f26473dc
https://doi.org/10.1158/1078-0432.c.6531203
https://doi.org/10.1158/1078-0432.c.6531203
Autor:
Johann de Bono, Mohammed M. Dar, C. Martin Curtis, Bo Ma, A. Benjamin Suttle, Roger E. McLendon, Jorge Barriuso, Jeffrey Raizer, Steve Rosenfeld, Tom Mikkelsen, Louis Nabors, Patrick Y. Wen, Morris D. Groves, David A. Reardon
Purpose: Increased mitogenic signaling and angiogenesis, frequently facilitated by somatic activation of EGF receptor (EGFR; ErbB1) and/or loss of PTEN, and VEGF overexpression, respectively, drive malignant glioma growth. We hypothesized that patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b869cb9e4bce5879511f2bc803cbfdf7
https://doi.org/10.1158/1078-0432.c.6521861.v1
https://doi.org/10.1158/1078-0432.c.6521861.v1
Autor:
Patrick Roth, Susan Moran, Ge Wei, Francesca Avogadri, Cindy Xu, Steven Rowsey, Harris S. Soifer, Pierre Giglio, Cristóbal Belda-Iniesta, Morris D. Groves, Paul M.J. Clement, Nicholas A. Butowski, Patrick Y. Wen, Filip Y.F. De Vos, Jeffrey J. Raizer, Vinay K. Puduvalli, Miguel J. Gil-Gil, Timothy F. Cloughesy, Juan Manuel Sepúlveda-Sánchez, Andrew B. Lassman
Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1563a5aa4a79c34480a823bb1d174a04
https://doi.org/10.1158/1078-0432.22483673
https://doi.org/10.1158/1078-0432.22483673
Autor:
Johann de Bono, Mohammed M. Dar, C. Martin Curtis, Bo Ma, A. Benjamin Suttle, Roger E. McLendon, Jorge Barriuso, Jeffrey Raizer, Steve Rosenfeld, Tom Mikkelsen, Louis Nabors, Patrick Y. Wen, Morris D. Groves, David A. Reardon
PDF file - 179K, Study design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::521e44faacc8ce15e43853e40cc4dec2
https://doi.org/10.1158/1078-0432.22450133.v1
https://doi.org/10.1158/1078-0432.22450133.v1
Autor:
Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, Miguel J. Gil-Gil, Vinay K. Puduvalli, Jeffrey J. Raizer, Filip Y.F. De Vos, Patrick Y. Wen, Nicholas A. Butowski, Paul M.J. Clement, Morris D. Groves, Cristóbal Belda-Iniesta, Pierre Giglio, Harris S. Soifer, Steven Rowsey, Cindy Xu, Francesca Avogadri, Ge Wei, Susan Moran, Patrick Roth
Publikováno v:
Clin Cancer Res
Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1–3 inhibitor, infigratinib (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1992e8a27b1403d69013c5615f19e6fc
https://www.zora.uzh.ch/id/eprint/230044/
https://www.zora.uzh.ch/id/eprint/230044/